Liposomal formulation and pharmacokinetic study of CPD409, a novel sodium channel blocker

Purpose CPD409 is a novel sodium channel blocker for pain control in chemotherapy-induced peripheral neuropathy with a very poor water solubility of less than 10 μg/mL. The aim of this study is to improve the aqueous solubility of CPD409 by using inclusion complexes with β-cyclodextrin (β-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD).